Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.